Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cono Ariti

Showing results (91-100 of 102) with videos related to

Pageof 11
Sort By:
JACC. Cardiovascular Interventions|March 24, 2017
Incidence, Patterns, and Associations Between Dual-Antiplatelet Therapy Cessation and Risk for Adverse Events Among Patients With and Without Diabetes Mellitus Receiving Drug-Eluting Stents: Results From the PARIS RegistryMichela Faggioni, Usman Baber, Samantha Sartori, et al.
The American Journal of Cardiology|August 6, 2017
Causes, Timing, and Impact of Dual Antiplatelet Therapy Interruption for Surgery (from the Patterns of Non-adherence to Anti-platelet Regimens In Stented Patients Registry)Mikkel Schoos, Jaya Chandrasekhar, Usman Baber, et al.
Lancet (London, England)|September 6, 2013
Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational studyRoxana Mehran, Usman Baber, Philippe Gabriel Steg, et al.
Circulation. Cardiovascular Interventions|March 29, 2020
Bleeding Risk, Dual Antiplatelet Therapy Cessation, and Adverse Events After Percutaneous Coronary Intervention: The PARIS RegistrySabato Sorrentino, Samantha Sartori, Usman Baber, et al.
Circulation. Cardiovascular Interventions|June 6, 2018
Incidence, Patterns, and Impact of Dual Antiplatelet Therapy Cessation Among Patients With and Without Chronic Kidney Disease Undergoing Percutaneous Coronary Intervention: Results From the PARIS Registry (Patterns of Non-Adherence to Anti-Platelet Regimens in Stented Patients)Usman Baber, Shawn X Li, Rebecca Pinnelas, et al.
Circulation. Cardiovascular Interventions|April 19, 2019
Influence of Baseline Anemia on Dual Antiplatelet Therapy Cessation and Risk of Adverse Events After Percutaneous Coronary InterventionMichela Faggioni, Usman Baber, Samantha Sartori, et al.
The American Journal of Cardiology|October 2, 2018
Dual Antiplatelet Therapy Cessation and Adverse Events After Drug-Eluting Stent Implantation in Patients at High Risk for Atherothrombosis (from the PARIS Registry)Sabato Sorrentino, Gennaro Giustino, Usman Baber, et al.
Thrombosis and Haemostasis|August 1, 2019
Geographical Variations in Patterns of DAPT Cessation and Two-Year PCI Outcomes: Insights from the PARIS RegistryBirgit Vogel, Jaya Chandrasekhar, Usman Baber, et al.
Clinical Cardiology|May 21, 2015
Mineralocorticoid receptor antagonist pretreatment to MINIMISE reperfusion injury after ST-elevation myocardial infarction (the MINIMISE STEMI Trial): rationale and study designHeerajnarain Bulluck, Georg M Fröhlich, Shah Mohdnazri, et al.
JACC. Cardiovascular Interventions|May 25, 2019
Dual-Antiplatelet Therapy Cessation and Cardiovascular Risk in Relation to Age: Analysis From the PARIS RegistryLauren C Joyce, Usman Baber, Bimmer E Claessen, et al.
Pageof 11

Showing results (91-100 of 102) with videos related to

Sort By:
Pageof 11
JACC. Cardiovascular Interventions|March 24, 2017
Incidence, Patterns, and Associations Between Dual-Antiplatelet Therapy Cessation and Risk for Adverse Events Among Patients With and Without Diabetes Mellitus Receiving Drug-Eluting Stents: Results From the PARIS RegistryMichela Faggioni, Usman Baber, Samantha Sartori, et al.
The American Journal of Cardiology|August 6, 2017
Causes, Timing, and Impact of Dual Antiplatelet Therapy Interruption for Surgery (from the Patterns of Non-adherence to Anti-platelet Regimens In Stented Patients Registry)Mikkel Schoos, Jaya Chandrasekhar, Usman Baber, et al.
Lancet (London, England)|September 6, 2013
Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational studyRoxana Mehran, Usman Baber, Philippe Gabriel Steg, et al.
Circulation. Cardiovascular Interventions|March 29, 2020
Bleeding Risk, Dual Antiplatelet Therapy Cessation, and Adverse Events After Percutaneous Coronary Intervention: The PARIS RegistrySabato Sorrentino, Samantha Sartori, Usman Baber, et al.
Circulation. Cardiovascular Interventions|June 6, 2018
Incidence, Patterns, and Impact of Dual Antiplatelet Therapy Cessation Among Patients With and Without Chronic Kidney Disease Undergoing Percutaneous Coronary Intervention: Results From the PARIS Registry (Patterns of Non-Adherence to Anti-Platelet Regimens in Stented Patients)Usman Baber, Shawn X Li, Rebecca Pinnelas, et al.
Circulation. Cardiovascular Interventions|April 19, 2019
Influence of Baseline Anemia on Dual Antiplatelet Therapy Cessation and Risk of Adverse Events After Percutaneous Coronary InterventionMichela Faggioni, Usman Baber, Samantha Sartori, et al.
The American Journal of Cardiology|October 2, 2018
Dual Antiplatelet Therapy Cessation and Adverse Events After Drug-Eluting Stent Implantation in Patients at High Risk for Atherothrombosis (from the PARIS Registry)Sabato Sorrentino, Gennaro Giustino, Usman Baber, et al.
Thrombosis and Haemostasis|August 1, 2019
Geographical Variations in Patterns of DAPT Cessation and Two-Year PCI Outcomes: Insights from the PARIS RegistryBirgit Vogel, Jaya Chandrasekhar, Usman Baber, et al.
Clinical Cardiology|May 21, 2015
Mineralocorticoid receptor antagonist pretreatment to MINIMISE reperfusion injury after ST-elevation myocardial infarction (the MINIMISE STEMI Trial): rationale and study designHeerajnarain Bulluck, Georg M Fröhlich, Shah Mohdnazri, et al.
JACC. Cardiovascular Interventions|May 25, 2019
Dual-Antiplatelet Therapy Cessation and Cardiovascular Risk in Relation to Age: Analysis From the PARIS RegistryLauren C Joyce, Usman Baber, Bimmer E Claessen, et al.
Pageof 11